Tetralogic Pharmaceuticals Corp Stock Performance
| TLOG Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 1.15, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, TetraLogic Pharmaceuticals will likely underperform. At this point, TetraLogic Pharmaceuticals has a negative expected return of -0.79%. Please make sure to validate TetraLogic Pharmaceuticals' market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to decide if TetraLogic Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days TetraLogic Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 13.1 M | |
| Total Cashflows From Investing Activities | 35.4 M |
TetraLogic |
TetraLogic Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.02 in TetraLogic Pharmaceuticals Corp on September 30, 2025 and sell it today you would lose (0.01) from holding TetraLogic Pharmaceuticals Corp or give up 50.0% of portfolio value over 90 days. TetraLogic Pharmaceuticals Corp is currently does not generate positive expected returns and assumes 6.2994% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of pink sheets are less volatile than TetraLogic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TetraLogic Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TetraLogic Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as TetraLogic Pharmaceuticals Corp, and traders can use it to determine the average amount a TetraLogic Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TLOG |
Based on monthly moving average TetraLogic Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TetraLogic Pharmaceuticals by adding TetraLogic Pharmaceuticals to a well-diversified portfolio.
TetraLogic Pharmaceuticals Fundamentals Growth
TetraLogic Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of TetraLogic Pharmaceuticals, and TetraLogic Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TetraLogic Pink Sheet performance.
| Return On Asset | -0.2 | |||
| Current Valuation | 458.72 K | |||
| Shares Outstanding | 24.47 M | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 0.40 X | |||
| EBITDA | (43.15 M) | |||
| Cash And Equivalents | 5.89 M | |||
| Cash Per Share | 0.24 X | |||
| Total Debt | 28.33 M | |||
| Debt To Equity | 4.17 % | |||
| Book Value Per Share | (1.25) X | |||
| Cash Flow From Operations | (34.89 M) | |||
| Earnings Per Share | (1.65) X | |||
| Total Asset | 64.02 M | |||
| Retained Earnings | (175.56 M) | |||
| Current Asset | 21.97 M | |||
| Current Liabilities | 3.66 M | |||
About TetraLogic Pharmaceuticals Performance
By analyzing TetraLogic Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into TetraLogic Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if TetraLogic Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TetraLogic Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Tetralogic Pharmaceu operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 29 people.Things to note about TetraLogic Pharmaceuticals performance evaluation
Checking the ongoing alerts about TetraLogic Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for TetraLogic Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TetraLogic Pharmaceuticals generated a negative expected return over the last 90 days | |
| TetraLogic Pharmaceuticals has high historical volatility and very poor performance | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing TetraLogic Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TetraLogic Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining TetraLogic Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TetraLogic Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TetraLogic Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TetraLogic Pharmaceuticals' pink sheet. These opinions can provide insight into TetraLogic Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for TetraLogic Pink Sheet analysis
When running TetraLogic Pharmaceuticals' price analysis, check to measure TetraLogic Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TetraLogic Pharmaceuticals is operating at the current time. Most of TetraLogic Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of TetraLogic Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TetraLogic Pharmaceuticals' price. Additionally, you may evaluate how the addition of TetraLogic Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |